Navigation Links
TAXUS(R) Express(TM) Stent Shows Similarly Low Re-intervention Rates in Diabetic Patients Compared to Non-Diabetics in ARRIVE 1 and 2 registries
Date:3/29/2008

NATICK, Mass. and CHICAGO, March 29 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced results from an analysis of 4,772 patients from its TAXUS ARRIVE 1 and 2 registries, designed to assess the performance of the TAXUS(R) Express2(TM) Paclitaxel-Eluting Coronary Stent System in real-world practice. The one-year pooled ARRIVE data confirmed the known higher mortality rate for diabetics versus non-diabetics with cardiovascular disease(1), but showed that the TAXUS Stent had similarly low rates of stent-related cardiac death, myocardial infarction (MI), stent thrombosis, and major cardiac events (MCE) across those two patient subsets. The study also showed similar rates of target vessel re-intervention (TVR) and TAXUS-related TVR in indicated patients(2) per the European Union (EU) label, whether or not they had diabetes. Analysis of the data was presented by D. Lynn Morris, M.D., at the SCAI Annual Scientific Sessions in Partnership with the ACC/i2 Summit in Chicago.

The pooled analysis included one-year data on 1,530 medication-requiring diabetic patients and 3,242 non-diabetic patients from the ARRIVE registry program. Due to significant disparity in baseline characteristics between diabetic and non-diabetic patients, propensity score analysis was used to allow for adjustment of baseline differences (other than the presence of diabetes) between the two groups.

The results showed diabetic patients had the well-known higher overall adjusted one-year mortality rate than patients without diabetes (3.7% vs. 2.3%, respectively, p=0.016), with the difference being driven by the cardiac death rate (2.3% vs. 1.2%, p=0.014), and reflecting the more advanced cardiac disease associated with diabetes. How
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Five-Year Data From Taxus II Clinical Trial Highlights Safety and Efficacy of Taxus(R) Stent Compared to Bare-Metal Stent
2. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
3. Boston Scientific to Release Broad Range of Clinical Trial Data Reinforcing Safety and Efficacy of Taxus(R) Coronary Stent Systems at TCT 2007
4. Preliminary Results of Randomized Pilot Study Show Comparable Efficacy for OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) and Boston Scientifics Taxus(R) Stent in Patients at High Risk of Restenosis
5. Boston Scientific PROMUS(TM) and TAXUS(R) Stents Continue Strong Performance in Safety and Efficacy Measures
6. Positive Five-Year Safety Data for TAXUS(R) Stent Reported in Boston Scientific Trial
7. OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) has Lower MACE Rate than TAXUS(R) and CYPHER(R) Stents in Clinical Trial
8. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
9. Two-Year Outcomes From Large Head-to-Head Clinical Trial Indicate Similar Safety Profile in Diabetic Patients for Cypher(R) Sirolimus-Eluting Coronary Stent and Taxus Stent
10. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
11. Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... ALBANY, New York , August 20, 2014 /PRNewswire/ ... published a new market report titled "Monochloroacetic Acid (MCA) ... Other Applications - Global Industry Analysis, Size, Share, Growth, ... acid market was valued at USD 817.1 million in ... by 2020, growing at a CAGR of 3.6% during ...
(Date:8/20/2014)... , Aug. 20, 2014 ... of the "Global Advanced Wound Care and ... - Size, Share, Global Trends, Company Profiles, Demand, ... 2013 - 2020" report to their offering. ... advanced wound care and closure market (types, applications, ...
(Date:8/20/2014)... 2014  Decision Resources Group finds that ... device market will expand through 2023 as ... fibrillation (AF). The increasing acceptance of ablation ... will spur adoption of premium-priced products designed ... loop diagnostic catheters, cryoablation catheters and contact ...
Breaking Medicine Technology:Global Monochloroacetic Acid (MCA) Market is Expected to Reach USD 1,046.7 million by 2020: Transparency Market Research 2Global Monochloroacetic Acid (MCA) Market is Expected to Reach USD 1,046.7 million by 2020: Transparency Market Research 3Global Monochloroacetic Acid (MCA) Market is Expected to Reach USD 1,046.7 million by 2020: Transparency Market Research 4Global Advanced Wound Care and Closure Market (Types, Applications, End User and Geography) - Forecast to 2020 2Electrophysiology Mapping and Ablation Device Market in Japan to Reach $1.1 Billion by 2023 2Electrophysiology Mapping and Ablation Device Market in Japan to Reach $1.1 Billion by 2023 3
... Services, Inc. (NYSE: WST ) announced today that it ... opens on Tuesday, November 3, 2009 and will follow with ... at 9:00 a.m. Eastern Time. To participate on the call ... A live broadcast of the conference call will be available ...
... Inc. (NYSE: HSP ), a leading global specialty ... the third quarter ended Sept. 30, 2009. Net sales ... earnings per share were $0.90. (Adjusted* measures exclude certain ... and the attached schedules.) , "Hospira delivered strong results ...
Cached Medicine Technology:West to Host 2009 Third Quarter Conference Call 2Hospira Reports Third-Quarter 2009 Results 2Hospira Reports Third-Quarter 2009 Results 3Hospira Reports Third-Quarter 2009 Results 4Hospira Reports Third-Quarter 2009 Results 5Hospira Reports Third-Quarter 2009 Results 6Hospira Reports Third-Quarter 2009 Results 7Hospira Reports Third-Quarter 2009 Results 8Hospira Reports Third-Quarter 2009 Results 9Hospira Reports Third-Quarter 2009 Results 10Hospira Reports Third-Quarter 2009 Results 11Hospira Reports Third-Quarter 2009 Results 12Hospira Reports Third-Quarter 2009 Results 13Hospira Reports Third-Quarter 2009 Results 14Hospira Reports Third-Quarter 2009 Results 15Hospira Reports Third-Quarter 2009 Results 16Hospira Reports Third-Quarter 2009 Results 17Hospira Reports Third-Quarter 2009 Results 18Hospira Reports Third-Quarter 2009 Results 19Hospira Reports Third-Quarter 2009 Results 20Hospira Reports Third-Quarter 2009 Results 21Hospira Reports Third-Quarter 2009 Results 22Hospira Reports Third-Quarter 2009 Results 23Hospira Reports Third-Quarter 2009 Results 24Hospira Reports Third-Quarter 2009 Results 25Hospira Reports Third-Quarter 2009 Results 26Hospira Reports Third-Quarter 2009 Results 27Hospira Reports Third-Quarter 2009 Results 28
(Date:8/20/2014)... Line: A study in Australia examined patient and ... (a marker of tumor cell growth) in an ... cancer in patients. , Author: ... Victoria, Australia, and colleagues. , Background: The ... cell division) has been connected with prognosis and ...
(Date:8/20/2014)... NY (PRWEB) August 20, 2014 Hundreds ... on behalf of women who were allegedly injured due ... forward in New Jersey’s Bergen County Superior Court, Bernstein ... issued on August 15, 2014, the Court has established ... for Mirena lawsuits that are part of the proceeding’s ...
(Date:8/20/2014)... HealthDay Reporter WEDNESDAY, Aug. ... cells grow may help doctors diagnose and treat the most ... have found that the deadliest skin cancers occur most often ... long history of sun exposure. These lesions also grow ... cell growth -- called "high mitotic rate" -- is ...
(Date:8/20/2014)... Aug. 20, 2014 A common approach to treating ... did not improve survival chances for people who suddenly ... at the University of Pittsburgh School of Medicine. , ... One , suggest acute hemodialysis, an aggressive method that ... may not provide a definitive benefit to the patient. ...
(Date:8/20/2014)... Research from Columbia University Medical Center shows that nerves ... and that blocking nerve signals using surgery or Botox ... The study was conducted by the laboratory of Timothy ... PhD, in Norway and is published in today,s issue ... long observed that human and mouse cancers contain a ...
Breaking Medicine News(10 mins):Health News:Patient, tumor characteristics for high-mitotic rate melanoma 2Health News:Mirena Lawsuit News: Case Management Order Issued in New Jersey Mirena Litigation, Bernstein Liebhard LLP Reports 2Health News:Mirena Lawsuit News: Case Management Order Issued in New Jersey Mirena Litigation, Bernstein Liebhard LLP Reports 3Health News:Mirena Lawsuit News: Case Management Order Issued in New Jersey Mirena Litigation, Bernstein Liebhard LLP Reports 4Health News:High-Risk Melanomas Often on Head or Neck, Study Finds 2Health News:High-Risk Melanomas Often on Head or Neck, Study Finds 3Health News:Pitt analysis questions use of acute hemodialysis treatment 2Health News:Severing nerves may shrink stomach cancers: Botox injections slow growth of tumors in mice 2
... Schweitzer (Chair of the Democratic Governors Association) and Maryland ... applauded President Obama,s reported selection of former DGA Chair ... Services. "Our health care system is broken, and Governor ... effort to fix it," Governor Schweitzer said. "In reforming ...
... rare, orphan and neglected diseases, launches iWish, which allows people to ... diseases through and image. In addition, people are invited to explain ... solutions for a rare disease or for the community in general. ... ...
... research presented at the 2009 American Orthopaedic Society of ... elbow ulnar collateral ligament (UCL) reconstruction prior to selection ... increase the risk of future injury or affect the ... no statistical difference between athletes who had undergone UCL ...
... Communication Service introduces vSling for capturing and distributing ... Smile Reminder will highlight their newest practice-to-patient ... Society Midwinter Meeting. Attracting thousands of dental practitioners ... platform for Smile Reminder to show its revenue ...
... experts urge better awareness of how machines work , , ... clearing the sidewalk quicker and easier, but those who ... with hand injuries and accidental amputations, say medical experts. ... not the type of injuries that can be reconstructed," ...
... 27 LCA-Vision Inc. (Nasdaq: LCAV ) ... independent research and proxy advisory firm, today recommended that ... of Directors and reject all of the proposals, including ... replacement Directors, in the Joffe Group,s consent solicitation. ...
Cached Medicine News:Health News:CheckOrphan Launches iWish to Commemorate Rare Disease Day 2Health News:CheckOrphan Launches iWish to Commemorate Rare Disease Day 3Health News:Elbow ligament reconstruction appears not to effect future professional advancement in baseball 2Health News:Smile Reminder Showcases Viral Marketing Tool at Chicago Dental Society's Midwinter Meeting 2Health News:Smile Reminder Showcases Viral Marketing Tool at Chicago Dental Society's Midwinter Meeting 3Health News:Snowblower Hand Injuries Often Extensive, Study Finds 2Health News:Glass Lewis Recommends Shareholders Support LCA-Vision Board of Directors and Reject All Three Proposals by Dissident Joffe Group 2Health News:Glass Lewis Recommends Shareholders Support LCA-Vision Board of Directors and Reject All Three Proposals by Dissident Joffe Group 3Health News:Glass Lewis Recommends Shareholders Support LCA-Vision Board of Directors and Reject All Three Proposals by Dissident Joffe Group 4
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: